Drugs / Gumarontinib
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05507294 | Mar → May 2021 | — | Haihe Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03457532 | Dec 2017 → Sep 2023 | neoplasm | Haihe Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03466268 | Sep 2017 → Jan 2023 | neoplasm | Haihe Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06980532 | Apr 2025 → Dec 2028 expected | colorectal cancer | Liu Huang | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04797702 | Apr 2021 → Jul 2023 | non-small cell lung carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04338243 | Nov 2019 → Dec 2020 | — | Haihe Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04270591 | Jul 2019 → Oct 2023 overdue | — | Haihe Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06947291 | Jun 2025 → Apr 2027 expected | cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06525350 | Jul 2024 → Dec 2026 expected | non-small cell lung carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06452433 | Jun 2024 → Dec 2027 expected | non-small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06908772 | Apr 2025 → Dec 2028 expected | — | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06829459 | Apr 2025 → Feb 2028 expected | non-small cell lung carcinoma | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gumarontinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03466268 ↗ |
| Known as | Glumetinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04797702 ↗ |
| Known as | Sc-c244 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594400 ↗ |
| Action | Inhibit | “MET inhibitor” PMID 39091606 ↗ Jul 2024 |
| Modality | Small molecule | — CHEMBL4594400 ↗ |
| Route | Oral | “a highly selective oral MET inhibitor” PMID 39091606 ↗ Jul 2024 |
| Target | MET | “MET inhibitor” PMID 39091606 ↗ Jul 2024 |